WO1996003993A3 - Modulation of thymocyte and t cell functional activity - Google Patents

Modulation of thymocyte and t cell functional activity Download PDF

Info

Publication number
WO1996003993A3
WO1996003993A3 PCT/US1995/009915 US9509915W WO9603993A3 WO 1996003993 A3 WO1996003993 A3 WO 1996003993A3 US 9509915 W US9509915 W US 9509915W WO 9603993 A3 WO9603993 A3 WO 9603993A3
Authority
WO
WIPO (PCT)
Prior art keywords
cgrp
administering
amount
modulation
inhibitor
Prior art date
Application number
PCT/US1995/009915
Other languages
French (fr)
Other versions
WO1996003993A2 (en
Inventor
Karen Bulloch
Bruce S Mcewen
Original Assignee
Univ Rockefeller
Karen Bulloch
Bruce S Mcewen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Karen Bulloch, Bruce S Mcewen filed Critical Univ Rockefeller
Publication of WO1996003993A2 publication Critical patent/WO1996003993A2/en
Publication of WO1996003993A3 publication Critical patent/WO1996003993A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to modulation of cell mediated immune responses, and to modulation or inhibition of thymocyte cancers or thymomas. In a first aspect, the present invention is directed to a method for suppressing an immune response by administering dehydroepiandrosterone (DHEA). In another aspect, the invention relates to a method for enhancing an immune response comprising administering an amount of an inhibitor of calcitonin gene related peptide (CGRP), such as the CGRP antagonist CGRP8-37, or an amount of an inhibitor of DHEA. The invention also provides a method for treating a thymic cancer or thymoma comprising administering an amount of calcitonin gene related peptide (CGRP) effective to induce apoptosis of thymic cancer or thymoma cells. The invention further provides a method for preventing tissue damage comprising administering an amount of an inhibitor of CGRP to inhibit apoptosis of cells in the area of the tissue damage. The invention also relates to a method for identifying an agent capable of inhibiting CGRP-mediated apoptosis.
PCT/US1995/009915 1994-08-05 1995-08-07 Modulation of thymocyte and t cell functional activity WO1996003993A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28686494A 1994-08-05 1994-08-05
US08/286,864 1994-08-05

Publications (2)

Publication Number Publication Date
WO1996003993A2 WO1996003993A2 (en) 1996-02-15
WO1996003993A3 true WO1996003993A3 (en) 1996-06-20

Family

ID=23100503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/009915 WO1996003993A2 (en) 1994-08-05 1995-08-07 Modulation of thymocyte and t cell functional activity

Country Status (1)

Country Link
WO (1) WO1996003993A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
CN1055640C (en) * 1996-11-29 2000-08-23 沃维汉 Human calcium degrading gene concerned peptide fatty composite and preparation thereof
JO3382B1 (en) 2008-12-23 2019-03-13 Amgen Inc Human cgrp receptor binding antibodies
EP3707157A4 (en) * 2017-11-06 2021-08-18 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
EP0408294A2 (en) * 1989-07-10 1991-01-16 Amylin Pharmaceuticals, Inc. Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders
WO1993021771A1 (en) * 1992-05-01 1993-11-11 University Of Utah Compositions and methods for regulating il-6 production in vivo
WO1993021911A1 (en) * 1992-05-06 1993-11-11 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
WO1994008589A1 (en) * 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
EP0408294A2 (en) * 1989-07-10 1991-01-16 Amylin Pharmaceuticals, Inc. Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders
WO1993021771A1 (en) * 1992-05-01 1993-11-11 University Of Utah Compositions and methods for regulating il-6 production in vivo
WO1993021911A1 (en) * 1992-05-06 1993-11-11 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
WO1994008589A1 (en) * 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLEMAN, D.L. ET AL: "Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice", DIABETOLOGICA, vol. 23, no. 1, pages 830 - 833 *
DAYNES, R.A. ET AL: "Regulation of murine lymphokine production in vitro", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 171, no. 4, pages 979 - 996 *
LUCAS J.A. ET AL: "Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White Fsub 1 mice fed dehydroisoandrosterone", J. CLIN. INVEST., 1985, 75/6 (2091-2093), USA *
MATSUNAGA A ET AL: "Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: lack of an effect on associated immunological abnormalities.", BIOCHIM BIOPHYS ACTA, SEP 15 1989, 992 (3) P265-71, NETHERLANDS *
SUZUKI, T. ET AL: "Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human Tcells", CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 61, no. 2, pages 202-211 *
TANNEN, R.H. ET AL: "Reduced weight gain and delay of Coomb's positive hemolytic anemia in NZB mice treated with dehydroepiandrosterone (DHEA)", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, vol. 41, pages 463A *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates

Also Published As

Publication number Publication date
WO1996003993A2 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
Reich et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
MY114347A (en) Synergistic therapeutic compositions and methods.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
CA2241981A1 (en) Method of inhibiting photoaging of skin
EP1748046A3 (en) Inhibitors of histone deacetylase
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
WO1993021942A3 (en) Use of mmp inhibitors
WO2001000198A3 (en) Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity
BR9811956B1 (en) naphthyridinones and pharmaceutical composition comprising them.
WO2001070675A3 (en) Inhibitors of histone deacetylase
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
WO2000021559A3 (en) Blocking factor b to treat complement-mediated immune disease
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
EP0643775A4 (en) Therapeutic compositions.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO1996003993A3 (en) Modulation of thymocyte and t cell functional activity
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
EP0627925A4 (en) Trypsin inhibitors.
ATE374618T1 (en) USE OF RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF FIBROTIC DISEASES
TR199802638T2 (en) Use of naaladase inhibitors in cancer treatment.
MX9805290A (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skin.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
Glinski et al. Neuropeptides in psoriasis: possible role of beta‐endorphin in the pathomechanism of the disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: CA,JP,US, EUROPEAN PATENT(AT,BE,DE,DK,FR,GB,IE,IT,LU,MC,NL,PT,SE)

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase